Dear readers of the AMNOG Monitor,

There is great anticipation surrounding the key points of a fundamental healthcare reform to be presented by Minister Nina Warken (CDU), which was announced for 30 March but had not yet been released at the time of going to press. According to the Minister, the healthcare system is to be made fit for the future through greater digitalisation, more effective management and more staff in the care sector.

In March, there were 12 new decisions on early benefit assessment (Fig. A), and 15 new procedures were initiated (Fig. B). Price changes are shown in Fig. C and the current EU HTA procedures are listed via the link below.

The first active substance, tovorafenib, subject to an EU HTA procedure, received a positive opinion from the CPMP working group on 26 February 2026. The marketing authorisation application for the active substance sasanlimab was withdrawn, meaning that the EU HTA procedure has also been discontinued; there are therefore currently 13 ongoing procedures.

AMNOG Monitor

A personal note

At the end of the year, long-planned changes have now taken place: Dr Peter Bramlage, with whom I have been on friendly terms for over 25 years, has left the IPPMed partnership and will continue to run IPPMed GmbH on his own, whilst my son Niklas Hankowitz, who is currently completing his specialist training at Regensburg University Hospital, has joined the IPPMed partnership. The company is now called the Institute for Pharmacology and Preventive Medicine – Dr Hankowitz & Partners – Doctors and Pharmacists. The address, registration number, VAT/tax number and bank details remain unchanged.

The AMNOG Monitor team has also undergone changes in the New Year: Mr Christian Rieke left the team at the end of the year and has been replaced by Nicolas Keller, who has been working for the AMNOG Monitor for almost 10 years and heads the programming team. Last year, under his leadership, we completely rebuilt the AMNOG Monitor using a new web framework and a new programming language, and completed the transition by the end of last year. This was necessary to enable us to process even larger volumes of data in a very short time. We will thus integrate the EU HTA as well as other large datasets, e.g. Dossier Module 4, clinical trials from www.clinicaltrials.gov, and the latest prescribing information (SmPC) provided by Rote Liste, whilst simultaneously achieving faster processing speeds. In the coming months, we will also modernise the AMNOG Monitor's visual design, improve its structure and offer many new features (effect measures with confidence intervals, p-values for significant patient-relevant endpoints, guidelines, MFN tracking, price tracking of ZVTs, combination discounts, documentation protection, etc.). We intend to utilise new AI capabilities such as chatbots, whilst maintaining close personal contact with you, for example through individual training sessions.

We therefore encourage you to take advantage of the opportunity to arrange a free training session with us at an early stage, as there is a great deal of new information to discuss.

New reimbursement prices of AMNOG products are available here.
EMA Positive Opinions for new drugs are shown here.

We look forward to hearing from you.
With this in mind

Dr. Johannes Hankowitz
Munich, 26th March 2026